Information for healthcare professionals only:

Mimpara ® (cinacalcet)
Biovitrum markets Mimpara® (Sensipar® in the US) in the Nordic Countries through a co-promotion agreement with Amgen. Mimpara® is a low molecular weight drug for the treatment of an overactive parathyroid gland related to:

• secondary hyperparathyroidism (SHPT) in kidney disease patients on dialysis  
• reduction of calcium stemming from parathyroid cancer
• reduction of calcium in patients with primary hyperparathyroidism (PHPT) for whom operation of the glands is not a viable option 

SHPT is characterized by elevated parathyroid hormone (PTH) levels and abnormal calcium and phosphorus levels in the body. Abnormal PTH, calcium and phosphorus levels are associated with increased risk of hospital admission and death, often as the result of coronary artery disease. Mimpara regulates PTH, calcium and phosphorus levels in the body. Normally, PTH keeps the blood’s calcium and phosphorus content to the exact levels needed to keep bone tissue, the heart, muscles, nerves and blood vessels working properly. When the kidneys are functioning normally, PTH regulates calcium and phosphorus levels in the body by transporting calcium and phosphorus in and out of the bone tissue.
 

When kidney function is impaired, calcium and phosphorus levels in the body are out of balance and the parathyroid glands produce too much PTH. This can lead to skeletal damage and is a risk factor for patients suffering from cardiac or vascular problems. Mimpara is used in the treatment of SHPT in kidney disease patients on dialysis as well as to counteract high levels of calcium in the blood of patients with parathyroid tumors.
 

PHPT is characterized by elevated calcium levels and elevated parathyroid hormone (PTH) levels. The overactive glands are normally removed surgically. However, for some patients surgery is not a viable option for medical reasons. Mimpara reduces calcium levels and is the only approved drug for inoperable patients.